





Disclaimer



This presentation does not provide full disclosure of all material facts relating to Camposol Holding PLC and its direct or indirect subsidiaries, including but not limited to Camposol S.A., a sociedad anónima organized under the laws of Peru (together, the "Company" or "Camposol"), the securities of Camposol or a potential offering of such securities and is not subject to liability for misrepresentations under applicable securities legislation.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in Camposol

This presentation does not constitute a prospectus and should under no circumstances be understood as an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Such an offer or solicitation can only be made by way of an effective registration statement or prospectus in accordance with the securities laws.

Certain statements herein are "forward-looking statements." Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "plans," "project," "target," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "potential," "can," "may," or the negative of these terms or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Camposol's current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond Camposol's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in the presentation. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.

No representation or warranty is given in respect of the information contained herein, and neither the delivery of this presentation nor any investment in Camposol securities will under any circumstances create any implication that Camposol has updated the information contained herein. Information throughout the presentation provided by sources other than Camposol has not been independently verified. Differences between past performance and actual results may be material and adverse.

This presentation includes unaudited non-IFRS financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin. We present non-IFRS measures when we believe that the additional information is useful and meaningful to investors. Non-IFRS financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-IFRS financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board.

Neither this presentation nor the information contained herein may be copied, reproduced, disclosed or distributed in whole or in part at any time without the prior written consent of Camposol. By accepting this presentation, the recipient acknowledges and agrees that this presentation and all of the information contained herein is confidential and subject to the confidentiality email previously acknowledged by the recipient. Without limiting the generality of the foregoing, the recipient will not reproduce this presentation in whole or in part and will hold all information contained in this presentation and the fact that Camposol is considering a potential initial public offering in confidence.

Speakers Today



Ricardo Naranjo Fernandez CEO





Jossue Yesquen Lihim IRO




Key Developments 1H 2025














- In the first half of 2025, Camposol delivered an EBITDA of USD 67.0 million, a solid first-half result, supported by strong agricultural strategies and an outstanding approach to commercial execution and fruit allocation.
- Our strategic focus on developing new markets and extending the blueberry production window allowed us to increase volume sold during the first half of 2025, leading to a higher contribution margin in this segment compared to the same period last year.



- We also had a highly successful grape season, a positive trend that began in late 2024 and carried through 2025.
- The mango business performed well, returning to historical profitability levels. While 2024 benefited from extraordinary pricing conditions due to tight market supply a context we capitalized on this year reflected normalized market dynamics with solid, albeit lower, returns compared to last year.
- Debt management remains a top priority in 2025. Our Net Debt/EBITDA ratio is below 3x. It is important to note that in the second and third quarters, we typically increase short-term working capital debt as the avocado and blueberry campaigns begin, and subsequently reduce total debt levels once again during the fourth and first quarters.




Operational overview 1H 2025 - Key metrics



Volume Sold (MT)






Volume sold in 1H 2025 increased by 38% compared to 1H 2024, primarily due to higher volumes of blueberry, grape and mangoes.

Revenue USD (MM)






Revenue in 1H 2025 was 22% higher than in 1H 2024, driven by increased sales of blueberries and grapes.

EBITDA USD (MM)






EBITDA for the first half of 2025 reached USD 67.0 million, representing an 8.7% increase compared to the same period in 2024.

Net Income USD (MM)






Net profit for the first quarter of 2025 was USD 16.0 million, down 17% compared to the same period in 2024.

Operational overview 1H 2025 - Crop performance YTD






Operational overview 1H 2025 - Crop performance LTM















Planted Hectares

2,729 o Peru:

Own Var: 64

Total: 2,715




































Colombia 1,358

Total has: 3,962









o Peru: 1,007

Uruguay: 869


Chile: 149

Total has: 2,024



Operational overview 1H 2025 - EBITDA reconciliation





Blueberry: Strategic pruning concentrated more volume in 1H25, reinforcing year-round supply model, opening new markets, improving efficiency, and increasing gross margin to 44% (vs. 35% in 1H24).


Mango: Strong 37% gross profit margin despite normalized pricing, confirming solid execution and profitability.

Other: Grapes: Strong first half with 33% higher prices, 27% gross margin, and 24% lower costs thanks to better yields and improved crop management.

Selling expenses: The increase was mostly due to higher international shipping costs, as we moved larger volumes of fruit during the first half of 2025.

Operational overview 1H 2025 - Cash flow





Strong cash collections in 1H 2025 from 2024-2025 blueberry and grapes campaign supported timely supplier payments.

Debt: 50.2M short-term debt increase in 1H 2025 directly related to the start o the avocado and blueberry campaigns.

Capex: focused on short-term growth and risk mitigation, plus new lab and nursery to scale our proprietary genetics and replanting program.

Dividends: dividend distribution of USD 28.5M related to the profit of 2024.




Operational overview 1H 2025 - Leverage and Debt profile



Debt Profile


We increased debt aligned with the start of the avocado and blueberry harvesting seasons. At the same time, we maintained a strong cash position of USD 29.6 million. Combined with committed credit lines, this covers most of short-term maturities.



Total financing credit lines vs short term debt

☐ Total available credit line ☐ Working capital short term debt

Total available credit line / WKSTD




Strong liquidity support: Available credit lines represent 1.6x our working capital debt. We continue to strengthen our solid relationships with financial institutions.

Operational overview 1H 2025 - Leverage and Debt profile




Debt history

Improved debt structure: Short-term debt represents less than 25% of total debt, reflecting two years of disciplined deleveraging.



1Q -23 2Q - 23 3Q - 23 4Q - 23 1Q -24 2Q -24 3Q -24 4Q -24 1Q -25 2Q -25

Net Debt / EBITDA



Net debt-to-EBITDA at 2.59x, marking the fourth consecutive quarter below our 3.5x threshold — reflecting the positive impact of our strategy and consistent financial discipline.



Financial Statements 1H 2025 - Preliminary Income Statement



	For the period ended	
	30.06.2025	30.06.2024
Revenue	222,140	182,217
Cost of sales	(137,148)	(115,231)
Gross profit before adjustment for biological assets	84,992	66,986
Net adjust. from change in fair value of bio. Assets	3,952	3,980
Profit after adjustment from biological assets	88,944	70,966
Selling expenses	(32,251)	(19,534)
Administrative expenses	(12,427)	(12,163)
Other expenses	(6,606)	(2,379)
Otherincome	800	1,737
Net foreign exchange transactions gains (losses)	(914)	(1,955)
Operating profit	37,546	36,672
Share of gain (loss) of associated companies	413	(7)
Finance income	43	7,656
Finance costs	(19,235)	(22,399)
Profit (loss) before income tax	18,767	21,922
Income tax	(4,463)	(3,610)
Deferred income tax	1,698	998
Profit (loss) for the period	16,002	19,310

Financial Statements 1H 2025 - Preliminary Cash Flow



	For the Period ended	
	30.06.25	31.12.24
Cash flow from operating activities		
Collections	238,667	569,302
Payment to suppliers and employees	(206,270)	(388,020)
Interest paid	(17,101)	(42,144)
Income tax paid	(16,685)	(6,419)
Custom duties refund collections	1,145	3,088
Other collections / payments	537	2,308
Other payments	(1,259)	(2,321)
Net cash (used in) provided by operating activities	(966)	135,794
Cash flow from investing activities		
Purchases of property, plant and equipment	(6,342)	(9,318)
Investment in biological assets	(10,375)	(21,468)
Purchases of intangibles, excluding goodwill	(209)	(730)
Acquisition of subsidiary, net of cash acquired	-	(12,339)
Dividends from associates	-	398
Loans granted to related parties	-	(29,720)
Loans payment to related parties	-	21,055
Proceeds from sale of property, plant and equipment	184	545
Net cash used in investing activities	(16,742)	(51,577)
Cash flow from financial activities		
Bank loans proceeds	169,414	367,591
Bank loans payments	(119,232)	(423,883)
Dividends distribution	(28,500)	(3,400)
Principal elements of lease liabilities payments	(677)	(6,554)
Transaction costs	(153)	(973)
Leaseback proceeds	-	34,770
Principal elements of leaseback payments	(7,936)	(14,801)
Payments of long-term debt	(979)	(23,297)
Net cash provided by financial activities	11,937	(70,547)
Net (decrease) increase in cash during the period	(5,771)	13,670
Effect of movements in exchange rates on cash held	-	(2,197)
Cash and cash equivalents at beginning of period	35,376	23,903
Cash and cash equivalents at end of period	29,605	35,376

Financial Statements 1H 2025 - Preliminary Balance Sheet



	For the period ended	
	30.06.2025	31.12.2024
Assets		
Non-current assets		
Property, plant and equipment, net	714,268	697,000
Right of use asset	12,221	29,995
Investments in associated companies	18,180	18,165
Intangibles	10,219	11,338
Deferred income tax	5,279	3,581
Other accounts receivable	408	408
	760,575	760,487
Current assets		
Prepaid expenses	3,210	961
Current portion of biological assets	237,416	190,906
Inventories	56,475	80,292
Other accounts receivable	33,449	22,910
Trade accounts receivable	11,409	28,035
Cash and cash equivalents	29,605	35,376
	371,564	358,480
Total assets	1,132,139	1,118,967

	For the period ended		
	30.06.2025	31.12.2024	
Equity and liabilities			
Capital and reserve attributable to			
shareholders of the Company			
Share capital	10,000	10,000	
Revaluation of assets	172,973	172,973	
Retained earnings	156,135	161,707	
	339,108	344,680	
Minority interests	- 1,002	- 996	
Total equity	338,106	343,684	
Non-current liabilities			
Long-term debt	317,056	317,446	
Lease liability	75,168	84,979	
Deferred income tax	121,748	121,748	
	513,972	524,173	
Current liabilities			
Accounts payable to related companies	38	31	
Current portion of long-term debt	8,343	8,377	
Current portion of lease liability	22,357	20,719	
Trade payables	110,594	107,319	
Other payables	20,235	46,887	
Bank loans	118,494	67,777	
	280,061	251,110	
Total liabilities	794,033	775,283	
Total equity and liabilities	1,132,139	1,118,967	







Búscanos como CamposolCares en:







Búscanos como Camposol en:



Para más información por favor conectarse a: www.camposol.com.pe

For more information please log into: www.camposol.com.pe